Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Colorcon
Baxter
McKinsey
Johnson and Johnson

Last Updated: December 6, 2021

DrugPatentWatch Database Preview

Claims for Patent: 7,052,715

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,052,715
Title:Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
Abstract: The instant invention is directed toward a dermal delivery system composition comprising an aqueous base vehicle including American Emu oil, Isopropyl Palmitate (PROTACHEM IPP), PEG-8 (a polyethylene glycol available under the tradename PROTACHEM 400), methylsulfonylmethane (MSM) and SEPIGEL 305 (a combination including polyacrylamide/C.sub.13 C.sub.14 Iso-paraffin and Laureth-7), in combination with an analgesic composition, such as ibuprofen, and to processes for the manufacture and use thereof.
Inventor(s): Fishman; Robert (Pembroke Pines, FL)
Assignee: All Natural FMG, Inc. (N. Palm Beach, FL)
Application Number:10/412,626
Patent Claims:1. An alcohol-free analgesic composition effective for transdermal delivery consisting essentially of: about 3% Emu Oil, about 3% Isopropyl Palmitate, about 4% PEG-8, about 0.75% methylsulfonylmethane, and a gelling agent including a combination of about 40% polyacrylamide, about 15% C.sub.13 C.sub.14 Iso-paraffin, about 5% Laureth-7 and sterile water sufficient to make 100% in an amount effective for gelling, about 10% of an analgesic composition, and sterile water sufficient to make 100%.

2. A composition for treating the discomfort of pain and/or inflammation in a patient comprising: about 3% Emu Oil, about 3% Isopropyl Palmitate, about 4% PEG-8, about 0.75% methylsulfonylmethane, and a gelling agent including a combination of about 40% polyacrylamide, about 15% C.sub.13 C.sub.14 Iso-paraffin, about 5% Laureth-7 and sterile water sufficient to make 100% in an amount effective for gelling, about 10% of an analgesic composition, and sterile water sufficient to make 100%.

3. A process for treating the discomfort of pain and/or inflammation and pain in a patient comprising: identifying a location of pain and/or inflammation in a patient; identifying a location or trigger points associated with pain/or inflammation in a patient; transdermally delivering to at least one location of trigger point said points an analgesic composition consisting essentially of about 3% Emu oil, 3% Isopropyl Palmitate and about 4% PEG-8, about 0.75% methylsulfonylmethane, a gelling agent including a combination of about 40% polyacrylamide, about 15% C.sub.13 C.sub.14 Iso-paraffin, about 5% Laureth-7 and sterile water sufficient to make 100% in an amount effective for gelling, about 10% of an analgesic composition, and sterile water sufficient to make 100%; whereby the discomfort of said pain and/or inflammation is treated.

4. A process for manufacturing an alcohol-free analgesic composition effective for transdermal delivery comprising: providing said analgesic composition; providing about 3% Emu oil in a high speed mixing apparatus; adding said analgesic composition to said Emu oil and mixing until a homogeneously blended composition is formed; adding about 3% Isopropyl Palmitate and about 4% PEG-8 to said homogeneously blend, and mixing for approximately 30 minutes; adding sterile water and mixing for approximately 5 minutes, to homogeneity; adding about 3% of a gelling agent including a combination of about 40% polyacrylamide, about 15% C.sub.13 C.sub.14 Iso-paraffin, about 5% Laureth-7 and sterile water sufficient to make 100%, and blending to achieve homogeneity and a gel-like consistency; and adding additional said gelling agent in 1% increments, if necessary, until desired gel consistency is achieved.

5. The product produced by the process of claim 4.

6. An alcohol-free transdermal delivery system consisting essentially of: about 3% Emu oil, about 3% Isopropyl Palmitate, about 4% PEG-8, about 0.75% methylsulfonylmethane, a gelling agent including a combination of about 40% polyacrylamide, about 15% C.sub.13 C.sub.14 Iso-paraffin, about 5% Laureth-7 and sterile water sufficient to make 100% in an amount effective for gelling, and sterile water sufficient to make 100%.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Mallinckrodt
AstraZeneca
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.